Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00539500 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00539500: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00539500 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00539500, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the possibility of tumor cells contaminating (appearing in) the stem cells that are reinfused into participants.
Interventions
- DRUG Melphalan
- DRUG Carboplatin
- DRUG Etoposide
- PROCEDURE Stem Cell Infusion
- DEVICE ClinicMACS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00539500
The ClinicalTrials.gov registry entry for NCT00539500 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT00539500 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00539500 about?
NCT00539500 is a clinical study titled "Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma". The goal of this clinical research study is to learn how long it takes for certain types of transplanted stem cells to produce new blood cells. The safety of this treatment will also be studied. Finally, researchers want to learn if collecting the cells with the CliniMACS device can decrease the pos...
What is the current status of trial NCT00539500?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-10. Estimated completion is 2012-09-05.
What interventions are being tested in trial NCT00539500?
The interventions under investigation include: Melphalan (DRUG), Carboplatin (DRUG), Etoposide (DRUG), Stem Cell Infusion (PROCEDURE), ClinicMACS (DEVICE).
Who is sponsoring clinical trial NCT00539500?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.